| Erika Sosa, FNP-BC | |
|
450 W Central Pkwy, Altamonte Springs, FL 32714-2436 | |
| (407) 767-8554 | |
| (407) 767-9121 |
| Full Name | Erika Sosa |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 450 W Central Pkwy, Altamonte Springs, Florida |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1669942181 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | APRN11000124 (Florida) | Primary |
| Entity Name | Orlando Heart & Vascular Institute, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942795000 PECOS PAC ID: 8729332820 Enrollment ID: O20181107003619 |
News Archive
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).
Long-term light smokers appear to be at greater risk for lung function decline, emphysema and obstructive lung disease than heavy smokers who quit, according to new research presented at the ATS 2018 International Conference.
People with brain tumors, and those who love and care for them, will observe Brain Tumor Awareness Week with three educational and celebratory events sponsored by the University of Rochester Medical Center and James P. Wilmot Cancer Center.
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced clinical and preclinical data from its lead program, KAI-4169, at the Endocrine Society's 93rd Annual Meeting (ENDO 2011) taking place in Boston, June 4-7, 2011. KAI-4169 is a novel pharmaceutical agent being developed for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
In the latest in a series of experiments testing the use of stem cells to treat neurological disease, researchers at Henry Ford Hospital have shown for the first time that microscopic material in the cells offers a "robust" treatment for crippling stroke.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Erika Sosa, FNP-BC 3317 Ferndell Dr, Winter Park, FL 32792-2058 Ph: (407) 927-1824 | Erika Sosa, FNP-BC 450 W Central Pkwy, Altamonte Springs, FL 32714-2436 Ph: (407) 767-8554 |
News Archive
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).
Long-term light smokers appear to be at greater risk for lung function decline, emphysema and obstructive lung disease than heavy smokers who quit, according to new research presented at the ATS 2018 International Conference.
People with brain tumors, and those who love and care for them, will observe Brain Tumor Awareness Week with three educational and celebratory events sponsored by the University of Rochester Medical Center and James P. Wilmot Cancer Center.
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced clinical and preclinical data from its lead program, KAI-4169, at the Endocrine Society's 93rd Annual Meeting (ENDO 2011) taking place in Boston, June 4-7, 2011. KAI-4169 is a novel pharmaceutical agent being developed for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
In the latest in a series of experiments testing the use of stem cells to treat neurological disease, researchers at Henry Ford Hospital have shown for the first time that microscopic material in the cells offers a "robust" treatment for crippling stroke.
› Verified 4 days ago
Mercedes D Wierman, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 631 Palm Springs Dr, Suite 101, Altamonte Springs, FL 32701 Phone: 407-331-1121 | |
Mrs. Laura Wieber, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 106 Boston Ave Ste 105, Altamonte Springs, FL 32701 Phone: 407-553-7710 Fax: 866-445-1446 | |
Ms. Amanda Jean Aruto, FNP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 355 E Altamonte Dr Ste 1500, Altamonte Springs, FL 32701 Phone: 689-240-1719 | |
Ms. Madeline Japp, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 118 W Orange St, Altamonte Springs, FL 32714 Phone: 352-431-3940 | |
Janice Darden Krivan, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 475 Osceola St Ste 1100, Altamonte Springs, FL 32701 Phone: 407-831-6200 | |
Holly Nichole Young, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 251 Maitland Ave Ste 116, Altamonte Springs, FL 32701 Phone: 407-915-5643 Fax: 407-960-2602 | |
Lara Nicole Rimes, APRN, CPNP-PC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 475 Osceola St Ste 1100, Altamonte Springs, FL 32701 Phone: 407-831-6200 |